

**Supplementary Table 3.** Clinical characteristics according to the use of RAS blockade in Korean COVID-19 patients with diabetes based on the data from the National Health Insurance Review and Assessment Service of Korea

Characteristic	No RAS blockade user (n=505)	RAS blockade user (n=327)	P value
Age, yr	59.90±16.70	64.85±13.23	<0.0001
<40	60 (11.88)	9 (2.75)	0.0001
40 to <50	66 (13.07)	37 (11.31)	
50 to <60	108 (21.39)	67 (20.49)	
60 to <70	122 (24.16)	93 (28.44)	
70 to <80	92 (18.22)	75 (22.94)	
≥80	57 (11.29)	46 (14.07)	
Male sex	260 (51.49)	185 (56.57)	0.1505
Hypertension	242 (47.92)	326 (99.69)	<0.0001
Dyslipidemia	427 (84.55)	303 (92.66)	0.0005
Cardiovascular disease	125 (24.75)	102 (31.19)	0.0417
Cerebrovascular disease	62 (12.28)	43 (13.15)	0.7112
Chronic kidney disease	68 (13.47)	94 (28.75)	<0.0001
Asthma	151(29.90)	88 (26.91)	0.3519
COPD	47 (9.31)	25 (7.65)	0.4051
Cancer	118 (23.37)	66 (20.18)	0.2799
<b>Medication</b>			
Metformin	142 (28.12)	127 (38.84)	0.0012
Sulfonylurea	63 (12.48)	67 (20.49)	0.0019
Meglitinide	4 (0.79)	3 (0.92)	0.8467
TZD	17 (3.37)	24 (7.34)	0.0097
DPP-4i	133 (26.34)	130 (39.76)	<0.0001
SGLT2i	9 (1.78)	10 (3.06)	0.2288
AGI	4 (0.79)	3 (0.92)	0.8467
Insulin	1 (0.20)	1 (0.31)	0.7565
RAS blockade	0	327 (100.00)	<0.0001
ACEi	0	24 (7.34)	<0.0001
ARB	0	306 (93.58)	<0.0001
Beta blocker	62 (12.28)	76 (23.24)	<0.0001
Diuretics	32 (6.34)	79 (24.16)	<0.0001
CCB	83 (16.44)	176 (53.82)	<0.0001
Statin	174 (34.46)	192 (58.72)	<0.0001
Fibrate	16 (3.17)	16 (4.89)	0.2064

Values are presented as mean ± standard deviation or number (%).

RAS, renin-angiotensin system; COVID-19, coronavirus disease 2019; COPD, chronic obstructive pulmonary disease; TZD, thiazolidinedione; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium glucose cotransporter 2 inhibitor; AGI, alpha glucosidase inhibitor; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker.